Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735707 · ClinicalTrials.gov registry record · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
A Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19, sponsored by UMC Utrecht.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20,000
- Enrollment target
- 20
- Study locations
NCT02735707 is a Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19 that is actively recruiting participants, run by UMC Utrecht. The registered enrollment target is 20,000 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02735707, a Phase 3 study of Community-acquired Pneumonia, Influenza, COVID-19, is actively recruiting participants, sponsored by UMC Utrecht.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Conditions Studied
Interventions
- DRUG Amoxicillin-clavulanate
- DRUG Ceftriaxone
- DRUG Moxifloxacin or Levofloxacin
- DRUG Piperacillin-tazobactam
- DRUG Ceftaroline
Study Locations (20)
New South Wales
- Bankstown-Lidcombe Hospital - Bankstown
- Blacktown Hospital - Blacktown
- Campbelltown Hospital - Campbelltown
- Sutherland Hospital - Caringbah
- Concord Hospital - Concord
- Dubbo Base Hospital - Dubbo
- Northern Beaches Hospital - Frenchs Forest
- Nepean Hospital - Kingswood
Florida
- University of Florida - Jacksonville
Georgia
- Augusta University - Augusta
Illinois
- University of Illinois Health - Chicago
Louisiana
- Tulane Medical Center - New Orleans
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2016-04-11 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02735707
The ClinicalTrials.gov registry entry for NCT02735707 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UMC Utrecht, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Community-acquired Pneumonia, Influenza, COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Amoxicillin-clavulanate is the first listed.
NCT02735707 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New South Wales, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02735707 about?
NCT02735707 is a clinical study titled "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia". REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, R...
What is the current status of trial NCT02735707?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20,000 participants. The study started on 2016-04-11. Estimated completion is 2028-02.
What conditions does trial NCT02735707 study?
This clinical trial studies the following conditions: Community-acquired Pneumonia, Influenza, COVID-19.
What interventions are being tested in trial NCT02735707?
The interventions under investigation include: Amoxicillin-clavulanate (DRUG), Ceftriaxone (DRUG), Moxifloxacin or Levofloxacin (DRUG), Piperacillin-tazobactam (DRUG), Ceftaroline (DRUG).
Who is sponsoring clinical trial NCT02735707?
This trial is sponsored by UMC Utrecht, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735707 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.